Open Access Government produces compelling and informative news, publications, eBooks, and academic research articles for the public and private sector looking at health, diseases & conditions, workplace, research & innovation, digital transformation, government policy, environment, agriculture, energy, transport and more.
Home 2024
Archives
Unraveling the potential of antisense therapies to target neuropilin 1 in the fight against...
Secarna Pharmaceuticals, the next-generation antisense drug discovery and development company, is developing novel approaches to successfully target Neuropilin 1 (NRP1), a promising target for the treatment of cancer.
Antisense therapies: A new approach to tackling challenging targets in areas of high unmet...
Alexander Gebauer, the Chief Executive Officer at Secarna Pharmaceuticals GmbH & Co. KG looks at a new approach to solve unmet medical needs with...
Secarna aims to expand the therapeutic toolbox against cancer
Current oncology treatments have significantly improved cancer survival rates, but more effective and safer therapeutics are needed.
Secarna: Next generation antisense therapeutics
Leading independent European antisense drug discovery company, Secarna, aims to bring novel and effective antisense therapeutic options to an increasing number of patients. CEO Alexander Gebauer tells us how.
Secarna Pharmaceuticals GmbH & Co. KG
Meet Secarna Pharmaceuticals GmbH & Co. KG: The leading independent European antisense drug discovery company
